

Original article

Prevalence and molecular characteristics of β -lactam resistance in non-typeable *Haemophilus influenzae* isolates in Korea

Eun-Young Kim¹, Yeon Chan Choi¹, Hyeon Jin Choi¹, Si Hyun Kim², Jihyun Cho³, Seok Hoon Jeong⁴, Dokyun Kim⁴, Hyun Soo Kim⁵, Soo Hyun Kim⁶, Young Ah Kim⁷, Young Ree Kim⁸, Nam Hee Ryoo⁹, Jong Hee Shin⁶, Kyeong Seob Shin¹⁰, Young Uh¹¹, Jeong Hwan Shin¹

¹Department of Laboratory Medicine and Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Korea

²Department of Biomedical Laboratory Science, Inje University, Gimhae, Korea.

³Department of Laboratory Medicine, Wonkwang University Medical School, Iksan, Korea

⁴Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

⁵Department of Laboratory Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea

⁶Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea


⁷Department of Laboratory Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea

⁸Department of Laboratory Medicine, Jeju National University College of Medicine, Jeju, Korea

⁹Department of Laboratory Medicine, Keimyung University School of Medicine, Daegu, Korea

¹⁰Department of Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Korea

¹¹Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea



OPEN ACCESS

pISSN : 2288-0585
eISSN : 2288-6850

Ann Clin Microbiol 2025 December, 28(4):23
<https://doi.org/10.5145/ACM.2025.28.4.4>

Correspondence to
Jeong Hwan Shin
E-mail: jhsmile@paik.ac.kr

Received: October 02, 2025

Revised: November 18, 2025

Accepted: November 27, 2025

© 2025 Korean Society of Clinical Microbiology.



This is an Open Access article which is freely available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abstract

Background: *Haemophilus influenzae* is the causative pathogen for various infectious diseases, such as respiratory infections, otitis media, sinusitis, and meningitis. This study aimed to investigate the prevalence and molecular characteristics of β -lactam resistance in non-typeable *H. influenzae* isolates in South Korea.

Methods: In total, 115 non-duplicated *H. influenzae* isolates were included in this study. Bacterial identification and serotyping were performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry and polymerase chain reaction (PCR) of *bexA*, respectively. Antimicrobial susceptibility was tested using the broth microdilution method. The production of β -lactamase was determined using nitrocefin disks. The presence of *blaTEM* and *blaROB* was confirmed using PCR. *ftsI* was analyzed to identify amino acid mutations in penicillin-binding protein (PBP) 3.

Results: Resistance rates to ampicillin, amoxicillin-clavulanate, and cefuroxime were 67.8%, 13.9%, and 32.2%, respectively. None of the isolates were resistant to cefotaxime or ceftriaxone. Among 78 ampicillin-resistant isolates, 71 were β -lactamase-producing ampicillin-resistant (BLPAR), and 7 were β -lactamase-non-producing ampicillin-resistant. All BLPAR isolates carried *blaTEM*, and none carried *blaROB*. Among 16 amoxicillin-clavulanate-resistant isolates, 15 β -lactamase producers harbored *blaTEM*. Four to 7 PBP3 mutations per isolate were detected in all 16 non- β -lactamase-producing ampicillin-resistant or cephalosporin-resistant isolates.

Conclusion: β -lactam resistance in non-typeable *H. influenzae* isolates is highly prevalent in

South Korea, primarily because of *bla*TEM and various PBP3 mutations. Therefore, continuous monitoring of antimicrobial resistance rates and mechanisms in non-typeable *H. influenzae* is necessary.

Keywords: Bacterial drug resistance, Beta-lactamases, Beta-lactam resistance, *Haemophilus influenzae*

Introduction

Background

Haemophilus influenzae is the causative pathogen for various infectious diseases such as respiratory infections, otitis media, sinusitis, and meningitis. *H. influenzae* is classified into six encapsulated groups (serotypes a–f) and a non-encapsulated group (non-typeable *H. influenzae*; NTHi). *H. influenzae* serotype b (Hib) is a well-known pathogen that causes serious invasive infections [1]. Recently, the number of invasive infections caused by Hib has significantly decreased with the global introduction of the Hib vaccine, whereas the number of infections caused by NTHi has increased [2,3]. NTHi is a common cause of bronchitis, acute otitis media, and sinusitis, particularly in individuals with underlying airway damage [2,3]. Unlike encapsulated strains, NTHi show high pharyngeal colonization rates, often exceeding 70%, with a particularly high prevalence in young children [3].

Ampicillin remains the first-line therapy for NTHi infection, but resistance has steadily increased [1,2,4]. This increase is driven by both the acquisition of β -lactamase and mutations in the penicillin-binding protein (PBP). Notably, PBP mutations are constantly evolving, resulting in cross-resistance to cephalosporins and carbapenems as well as increased ampicillin resistance. PBP3 mutations are reported to occur more frequently in Japan and South Korea [5,6].

In 2024, the World Health Organization highlighted ampicillin-resistant *H. influenzae* as one of the 15 most critical antimicrobial-resistant bacteria that pose a global threat to human health, calling for ongoing surveillance and monitoring [7]. In addition, β -lactamase-producing amoxicillin–clavulanate-resistant (BLPACR) *H. influenzae* has emerged and spread in a few countries [2,4].

Objectives

This study aimed to investigate the prevalence and molecular characteristics of β -lactam resistance in NTHi isolates in South Korea.

Methods

Study design

This was a retrospective surveillance study based on laboratory investigations. The study was described according to the Microbiology Investigation Criteria for Reporting Objectively: a framework for the reporting and interpretation of clinical microbiology data available at <https://bmcmicrobiology.biomedcentral.com/articles/10.1186/s12916-019-1301-1>.

Laboratory studies

Clinical isolates

In total, 115 non-duplicated *H. influenzae* isolates from respiratory (n = 104) and blood specimens (n = 11) from 10 sentinel hospitals in the Korean Global Antimicrobial Resistance Surveillance System from January to December 2023 (Gangnam Severance Hospital, National Health Insurance Service Ilsan Hospital, Wonju Severance Christian Hospital, Chungbuk National University Hospital, Chonnam National University Hospital, Inje University Busan Paik Hospital, Hallym University Dongtan Sacred Heart Hospital, Jeju National University Hospital, Keimyung University Dongsan Hospital, Wonkwang University Hospital) were included in this study [8]. Bacterial identification was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (VITEK MS system; bioMérieux) [8]. The presence of a capsule was determined by polymerase chain reaction (PCR) targeting *bexA* [9] and an aggregation assay using a polyclonal antigen (Difco™ *Haemophilus influenzae* Serotyping Antiserum, BD).

Antimicrobial susceptibility testing (AST)

AST was performed using the broth microdilution method with Sensititre™ KRIBVPD (TREK Diagnostic Systems Ltd.) for ampicillin, amoxicillin–clavulanate, cefuroxime, cefotaxime, ceftriaxone, and cefepime. Minimum inhibitory concentrations (MICs) were interpreted as susceptible (S), intermediate (I), resistant (R), or non-susceptible (NS) based on the Clinical and Laboratory Standards Institute M100-ED35 breakpoint [10]. *H. influenzae* ATCC49247 and *H. influenzae* ATCC49766 were used as quality-control isolates for AST.

Detection of β -lactamase genes

The production of β -lactamase was determined using nitrocefin disks (Sigma-Aldrich) by observing a color change on the disk from faint yellow to light brown.

The presence of *blaTEM* and *blaROB* was confirmed by PCR in all isolates [11]. The primers used for PCR are listed in Table 1. *Escherichia coli* ATCC35218 was used as the positive control for *blaTEM*. No positive control isolates for *blaROB* were available. Therefore, we synthesized *ROB-1* (National Center for Biotechnology Information Reference Sequence NG_049977; 918 bp) and transformed the pBHA vector by cloning the synthesized *ROB-1* into *E. coli* DH5 α . This isolate was used as the positive control for *blaROB*.

Detection of PBP3 mutations

The nucleotide sequence of *ftsI* was analyzed to identify amino acid mutations in PBP3 that confer resistance to β -lactam agents in β -lactamase-non-producing *H. influenzae* isolates showing resistance to ampicillin or cephalosporins [12]. The segment of *ftsI* used was located between nucleotides 997 and 1597 (amino acids 326–532). The *ftsI* allele was determined using PubMLST (<https://pubmlst.org/organisms/haemophilus-influenzae>). Twelve common amino acid changes (D350N/S, S357N, A368P/T, M377E/I, S385T, L389F, A437S, I449M/V, G490E/N, A502S/T/V, R517H/K, N526D/H/K) were assessed by comparing them with *H. influenzae* Rd KW20 reference (accession no. L42023).

Table 1. Primers used in the study

Target genes	Primer name	Sequences (5'→3')	Size (bp)	References
<i>bla</i> TEM	TEM (321)	TGGGTGCACGAGTGGGTTAC	526	[11]
	TEM (846)	TTATCCGCCTCCATCCAGTC		
<i>bla</i> ROB	ROB (419)	ATCAGCCACACAAGCCACCT	692	
	ROB (1110)	GTTTGCATTTGGTATGCGA		
<i>ftsI</i>	F1 (936)	GTTAATGCGTAACCGTGCAATTACC	704	
	F2 (1640)	ACCACTAATGCATAACGAGGATC		
	J1 (1048)	GATACTACGTCCTTTAAATTAAG	550	
	J2 (1598)	GCAGTAAATGCCACATACTTA		

Results

Antimicrobial resistance

All 115 *H. influenzae* isolates were confirmed as NTHi by serotyping. Among the 115 NTHi isolates, 67.8% (n = 78) and 8.7% (n = 10) were resistant and intermediate to ampicillin, respectively (Fig. 1). For amoxicillin–clavulanate, 13.9% (n = 16) and 24.3% (n = 28) were resistant and intermediate, respectively. Among the 78 ampicillin-resistant isolates, 38, 24, and 16 were susceptible, intermediate, and resistant to amoxicillin–clavulanate, respectively. All 16 amoxicillin–clavulanate-resistant isolates were resistant to ampicillin. Resistance and intermediate resistance to cefuroxime were observed in 32.2% (n = 37) and 27.8% (n = 32) of the isolates, respectively. All isolates were susceptible to cefotaxime and ceftriaxone, and 4.3% (n = 5) were resistant to cefepime.




Fig. 1. Antimicrobial susceptibility of *Haemophilus influenzae* isolates to ampicillin (a) and amoxicillin–clavulanate (b) in South Korea. S, susceptible; I, intermediate; R, resistant.

Detection of β-lactamase genes

Among 78 ampicillin-resistant isolates, β-lactamase-producing ampicillin-resistant (BLPAR) *H. influenzae*

was observed in 71 (91.0%) isolates. Seven (9.0%) isolates were β -lactamase-non-producing ampicillin-resistant (BLNAR) *H. influenzae*. All BLPAR isolates carried *blaTEM*, and none carried *blaROB*. All 10 isolates with intermediate resistance to ampicillin were β -lactamase non-producers. Among 44 β -lactamase-non-producing isolates, 16 showing resistance to ampicillin and/or cephalosporins were selected for *ftsI* sequencing. Among the 16 amoxicillin-clavulanate-resistant isolates, 15 β -lactamase producers (BLPACR) harbored *blaTEM*, and 1 isolate was a β -lactamase non-producer (Table 2). Among the 71 BLPAR isolates, 15 (21.1%), 19 (26.8%), and 37 (52.1%) were resistant, intermediate, and susceptible to amoxicillin-clavulanate, respectively. Among the 37 cefuroxime-resistant isolates, 23 (62.2%) were β -lactamase producers. Three (60.0%) of 5 cefepime non-susceptible isolates produced β -lactamases.

Table 2. Amoxicillin-clavulanate susceptibility of ampicillin-resistant *Haemophilus influenzae* isolates

Amoxicillin-clavulanate	Number of ampicillin-resistant isolates (%)		
	β -lactamase producer (n = 71)	β -lactamase non-producer (n = 7)	Total (n = 78)
Resistant	15 (93.8)	1 (6.2)	16 (100.0)
Intermediate	19 (79.2)	5 (20.8)	24 (100.0)
Susceptible	37 (97.4)	1 (2.6)	38 (100.0)

Values are presented as n (%).

Detection of PBP3 mutations

PBP3 mutations were analyzed in 16 β -lactamase non-producing isolates, including 2 ampicillin-resistant isolates, 9 cefuroxime-resistant isolates, and 5 isolates resistant to both ampicillin and cephalosporins (Table 3). Among isolates resistant to both ampicillin and cephalosporins, one isolate was resistant to ampicillin, amoxicillin-clavulanate, cefuroxime, and cefepime, and another isolate was resistant to ampicillin, cefuroxime, and cefepime. The remaining three isolates were resistant to ampicillin and cefuroxime.

Among the 12 known amino acid mutation points, 4–7 mutations per isolate were detected. S385T was most common (n = 16), followed by D350N (n = 15), S357N (n = 15), M377I (n = 13), L389F (n = 13), N526K (n = 11), R517H (n = 5), and A502T (n = 2). The most common *ftsI* allele was identified as allele 40 (n = 6). Alleles of 26, 16, 16-like, and 370 were detected in 4, 1, 1, and 1 isolates, respectively. Three isolates harbored this novel allele type (Table 3).

Table 3. PBP3 mutation profiles of β -lactamase-non-producing β -lactam-resistant *Haemophilus influenzae*

Resistance profile	Isolates (n = 16)	TEM	<i>ftsI</i> allele	Amino acid substitutions								
				D350	S357	M377	S385	L389	I449	A502	R517	N526
AM	2	-	40	N	N	I	T	F				K
AM, AMC, CXM, FEP	1	-	NEW	N	N		T					K
AM, CXM, FEP	1	-	NEW	N	N		T					K
AM, CXM	1	-	NEW	N	N		T					K
AM, CXM	2	-	26	N	N	I	T	F			H	
CXM	2	-	26	N	N	I	T	F			H	
CXM	4	-	40	N	N	I	T	F				K
CXM	1	-	16	N	N	I	T	F		T		K
CXM	1	-	16-like	N	N	I	T	F		T		K
CXM	1	-	370			I	T	F			H	

Abbreviations: AM, ampicillin; AMC, amoxicillin-clavulanate; CXM, cefuroxime; FEP, cefepime.

Discussion

Interpretation and comparison with previous studies

Hib infections have declined worldwide, including in South Korea, since the introduction of the Hib vaccine [2,13]. However, the number of NTHi infections is constantly increasing across all age groups, particularly in the elderly population [14]. Therefore, it is necessary to establish strategic approaches for antibiotic treatment of NTHi infections.

Ampicillin is a primary choice for treating infections caused by *H. influenzae*, and the major mechanism of ampicillin resistance is the production of β -lactamase [1-4]. The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) surveillance study (1999-2000) was performed using 2,948 *H. influenzae* isolates from 69 centers in 25 countries [15,16]. The PROTEKT study reported an overall resistance rate of 17.1% to ampicillin. However, the ampicillin resistance rate at 64.7% was significantly higher in South Korea. Subsequent reports from South Korea have confirmed that the resistance rate to ampicillin remains high. Kim et al. [17] reported that the resistance rate to ampicillin was 58.1% in 229 isolates between 2000 and 2005. The other two studies showed high ampicillin resistance rates of 73.8% in 2010 and 69.8% in 2014 from not-susceptible NTHi in children [6,12]. The ampicillin resistance rate of nasal carriage in healthy children between 2006 and 2007 was also high (51.9%, n = 223/430) in South Korea [18]. In our study, the ampicillin resistance and intermediate resistance rates were 67.8% and 8.7%, respectively, indicating that the resistance rate was still high.

In the expanded PROTEKT surveillance study, which collected 14,870 *H. influenzae* isolates from 137 centers in 38 countries, the β -lactamase production rate among all isolates was 15.0%, with marked inter-country variability (0%–69.7%) [19]. High rates of β -lactamase production were observed in Taiwan (67.9%, n = 127/187), South Korea (52.6%, n = 121/230), as well as in France (31.6%, n = 197/624), the USA (27.5%, n = 268/973), and Australia (22.9%, n = 141/617). Conversely, Italy (5.0%, n = 33/666), Germany (6.0%, n = 102/1,711), and Japan (8.0%, n = 147/1,833) demonstrated relatively low rates of β -lactamase production. No β -lactamase producers were found in seven countries. In our study, the β -lactamase production rate was similarly high at 61.7%, confirming that β -lactamase production remains elevated.

The two major genes encoding β -lactamases are *blaTEM* and *blaROB*, respectively. In our study, all BLPAR isolates (n = 71) were *blaTEM* producers, and there were no *blaROB* producers. Globally, *blaTEM* and *blaROB* accounted for 93.7% (range, 67.8%–100%) and 4.6% (range, 0%–30.0%) of β -lactamase-positive *H. influenzae* isolates between 1999 and 2003 [19]. Although *blaTEM* predominated in most countries, *blaROB* was highly prevalent in Mexico (30.0%), the USA (12.3%), and Canada (9.4%). In South Korea, the production of *blaTEM* has been consistently reported at high levels. It has been reported that the prevalence of *blaTEM* among BLPAR isolates was 99.2% (n = 120/121) in 1999–2003, 96.6% (n = 86/89) in 2000–2005, 91.6% (n = 272/283) in 2005–2006, 90.2% (n = 37/41) in 2010, and 90.0% (n = 18/20) in 2014 [6,12,17,19,20] in South Korea. In our study, 71 of 78 ampicillin-resistant isolates were classified as BLPAR carrying *blaTEM*. These findings confirm that ampicillin resistance in *H. influenzae* is

largely attributable to β -lactamase production, with a dominant contribution from *bla*TEM in South Korea, as previously reported.

In our study, all 7 BLNAR isolates showed low-level resistance (MIC = 4 μ g/mL). In contrast, the MICs of BLPAR isolates were as high as 16 μ g/mL or higher, except for one isolate. All BLNAR isolates in our study had diverse PBP3 mutation patterns. PBP3 mutations without *bla*TEM lead to low levels of ampicillin resistance [1], and our data showed similar results. High-level resistance to ampicillin can develop when BLNAR isolates acquire *bla*TEM; therefore, it is crucial to continuously monitor BLNAR isolates.

In Japan, the prevalence of BLNAR isolates has been steadily increasing and has remained at 60% since 2016 [21,22]. In particular, the number of BLNAR isolates with high MICs (range 4–32 μ g/mL) of ampicillin has been increasing significantly [21]. Most of them are β -lactamase negative high-level ampicillin-resistant *H. influenzae* (high-BLNAR) isolates with amino acid substitutions near the Ser-Ser-Asn motif (Ser357Asn, Met377Ile, Ser385Thr, and Leu389Phe) and an additional amino acid substitution (Asn526Lys or Arg517His). In our study, PBP mutations in all BLNAR isolates were similar to those of Japanese origin, although no isolates revealed MICs \geq 8 μ g/mL. This finding is similar to the features of BLNAR isolates recently reported in Korean children [6]. The elevated prevalence of BLNAR isolates in Japan has been attributed to the widespread use of oral cephalosporins, particularly cefdinir and cefditoren, for *H. influenzae* infection treatment [21,22]. Cephalosporins are often administered at relatively low doses that do not exert bactericidal effects but promote partial damage, thereby facilitating the emergence of mutations that support bacterial survival [1]. In South Korea, similar to Japan, the prescription of cephalosporins for pediatric patients remains relatively high, raising concerns about the potential increase in the prevalence of BLNAR isolates [22,23].

Resistance to amoxicillin–clavulanate can arise through several mechanisms, including β -lactamase overproduction, inhibitor-resistant *bla*TEM or *bla*ROB variants, novel β -lactamases, or alterations in PBPs superimposed on β -lactamase [1,24]. In our study, 15 of 71 BLPAR isolates were BLPACR, corresponding to 13% of all isolates, which was markedly higher than that reported previously [20]. Given the extensive use of cephalosporins and amoxicillin–clavulanate in South Korea, the rapid expansion of BLPACR isolates cannot be ruled out. Therefore, the continuous surveillance of their emergence and dissemination is imperative to guide effective treatment strategies and ensure antimicrobial stewardship.

Limitations

This study had a few limitations. First, a small number of isolates over only 1 year were included; thus, a larger number of isolates should be studied for a longer period of time in the future. Second, we investigated PBP mutations only in BLNAR isolates. Therefore, it is necessary to investigate mutation patterns, including those in BLPAR isolates, to identify the overall mutation pattern.

Conclusion

This study revealed a high prevalence of β -lactam antibiotic resistance among non-typeable *H. influenzae* isolates in South Korea. Most resistant isolates were β -lactamase producers carrying *bla*TEM, whereas a

smaller proportion exhibited resistance through PBP3 mutations. These findings highlight the need for the continued surveillance of antimicrobial resistance patterns in *H. influenzae*.

Ethics statement

This study was approved by the Institutional Review Board of Inje University Busan Paik Hospital (BPIRB NON2024-005) and was exempt from the requirement for patient consent.

Conflict of interest

Soo Hyun Kim has been an editorial board member since 2011, and Young Uh has been a statistical editor since 2024 of the *Annals of Clinical Microbiology*. However, these authors were not involved in the review of this article. No potential conflict of interest relevant to this article was reported.

Funding

This research was funded by the 2024 Research Grant from the Korean Society of Clinical Microbiology.

Data availability

The datasets generated during the current study are available from the corresponding author upon request.

References

1. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in *Haemophilus influenzae*. *Clin Microbiol Rev* 2007;20:368-89.
2. Heinz E. The return of Pfeiffer's bacillus: Rising incidence of ampicillin resistance in *Haemophilus influenzae*. *Microb Genom* 2018;4:e000214.
3. Gilsdorf JR. What the pediatrician should know about non-typeable *Haemophilus influenzae*. *J Infect* 2015;71 Suppl 1:S10-4.
4. Shiro H, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. Nationwide survey of the development of drug resistance in the pediatric field in 2000-2001, 2004, 2007, 2010, and 2012: evaluation of the changes in drug sensitivity of *Haemophilus influenzae* and patients' background factors. *J Infect Chemother* 2015;21:247-56.
5. Sanbongi Y, Suzuki T, Osaki Y, Senju N, Ida T, Ubukata K. Molecular evolution of beta-lactam-resistant *Haemophilus influenzae*: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan. *Antimicrob Agents Chemother* 2006;50:2487-92.
6. Park C, Kim KH, Shin NY, Byun JH, Kwon EY, Lee JW, et al. Genetic diversity of the *ftsI* gene in beta-lactamase-nonproducing ampicillin-resistant and beta-lactamase-producing amoxicillin-/clavulanic acid-resistant nasopharyngeal *Haemophilus influenzae* isolates isolated from children in South Korea. *Microb Drug Resist* 2013;19:224-30.
7. News brief: WHO releases 2024 bacterial priority pathogens list. *Am J Nurs* 2024;124:11.

8. Choi YC, Kim EY, Choi HJ, Kim SH, You E, Lee JY, et al. Evaluation of VITEK 2 system and VITEK MS system for the identification of *Haemophilus* species: a diagnostic accuracy study. *Ann Clin Microbiol* 2025;28:13.
9. van Ketel RJ, de Wever B, van Alphen L. Detection of *Haemophilus influenzae* in cerebrospinal fluids by polymerase chain reaction DNA amplification. *J Med Microbiol* 1990;33:271-6.
10. CLSI. Performance standards for antimicrobial susceptibility testing. 35th ed. CLSI M100-ED35. Wayne, PA: Clinical and Laboratory Standards Institute, 2025.
11. Tenover FC, Huang MB, Rasheed JK, Persing DH. Development of PCR assays to detect ampicillin resistance genes in cerebrospinal fluid samples containing *Haemophilus influenzae*. *J Clin Microbiol* 1994;32:2729-37.
12. Han MS, Jung HJ, Lee HJ, Choi EH. Increasing prevalence of group III penicillin-binding protein 3 mutations conferring high-level resistance to beta-lactams among nontypeable *Haemophilus influenzae* isolates from children in Korea. *Microb Drug Resist* 2019;25:567-76.
13. Wang S, Tafalla M, Hanssens L, Dolhain J. A review of *Haemophilus influenzae* disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. *Expert Rev Vaccines* 2017;16:1095-105.
14. Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP, et al. Epidemiology of invasive *Haemophilus influenzae* disease, Europe, 2007-2014. *Emerg Infect Dis* 2017;23:396-404.
15. Hoban D and Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of *Haemophilus influenzae* and *Moraxella catarrhalis* from community-acquired respiratory tract infections. *J Antimicrob Chemother* 2002;50 Suppl S1:49-59.
16. Inoue M, Lee NY, Hong SW, Lee K, Felmingham D. PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. *Int J Antimicrob Agents* 2004;23:44-51.
17. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in *Haemophilus influenzae* isolates isolated in Korea. *Antimicrob Agents Chemother* 2007;51:453-60.
18. Bae SM, Lee JH, Lee SK, Yu JY, Lee SH, Kang YH. High prevalence of nasal carriage of beta-lactamase-negative ampicillin-resistant *Haemophilus influenzae* in healthy children in Korea. *Epidemiol Infect* 2013;141:481-9.
19. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. Global distribution of TEM-1 and ROB-1 beta-lactamases in *Haemophilus influenzae*. *J Antimicrob Chemother* 2005;56:773-6.
20. Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, et al. Antimicrobial resistance in *Haemophilus influenzae* respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. *Antimicrob Agents Chemother* 2010;54:65-71.
21. Honda H, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, et al. Multiclonal expansion and high prevalence of β -lactamase-negative *Haemophilus influenzae* with high-level ampicillin resistance in Japan and susceptibility to quinolones. *Antimicrob Agents Chemother* 2018;62:e00851-18.
22. Hasegawa K, Yamamoto K, Chiba N, Kobayashi R, Nagai K, Jacobs MR, et al. Diversity of ampicillin-resistance genes in *Haemophilus influenzae* in Japan and the United States. *Microb Drug Resist* 2003;9:39-46.

23. Kim YA, Park YS, Youk T, Lee H, Lee K. Changes in antimicrobial usage patterns in Korea: 12-year analysis based on database of the National Health Insurance Service-National Sample Cohort. *Sci Rep* 2018;8:12210.
24. Doern GV, Brueggemann AB, Pierce G, Holley Jr. HP, Rauch A. Antibiotic resistance among clinical isolates of *Haemophilus influenzae* in the United States in 1994 and 1995 and detection of beta-lactamase-positive isolates resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. *Antimicrob Agents Chemother* 1997;41:292-7.